As of January 1, prostate cancer patients benefit for the first time from compensated drugs for the treatment of prostate cancer. These are bicalutamidum and cyproteronum - drugs that are fully compensated, IPN reports.
The National Health Insurance Company estimates that more than 3,700 patients will benefit from these preparations, which will be compensated from the compulsory health insurance funds.
The compensation for the new preparations amounts to about 9 million lei annually, money provided for in the compulsory health insurance funds.
"The list of compensated medicines and medical devices is periodically extended in order to increase citizens' access to these products, especially those who have difficulty in obtaining them", the CNAM adds.
